Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

January 10, 2025

Ryan Haumschild, PharmD, MS, MBA, CPEL
John Allan, MD

Opinion

Video

Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

Now Viewing

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP: 5.ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP: 6.MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP: 7.Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP: 8.Key Strategies for Preventing CRS and ICANS

EP: 9.Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP: 10.Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP: 11.Successful Implementation of Bispecific Therapies: Expert Recommendations

EP: 12.Benefits of Implementing Bispecific Therapies in the Community

EP: 13.Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP: 14.Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

Video content above is prompted by the following:

Several studies are evaluating the use of bispecific therapies in earlier lines of therapy for both diffuse large B-cell lymphoma and follicular lymphoma. What patient populations are most likely to benefit from bispecific therapies in earlier lines of therapy?